JP2022540921A - Ｋｒａｓまたはｈｒａｓ変異若しくは増幅を有するがんを処置する際に有用な方法 - Google Patents

Ｋｒａｓまたはｈｒａｓ変異若しくは増幅を有するがんを処置する際に有用な方法 Download PDF

Info

Publication number
JP2022540921A
JP2022540921A JP2022502559A JP2022502559A JP2022540921A JP 2022540921 A JP2022540921 A JP 2022540921A JP 2022502559 A JP2022502559 A JP 2022502559A JP 2022502559 A JP2022502559 A JP 2022502559A JP 2022540921 A JP2022540921 A JP 2022540921A
Authority
JP
Japan
Prior art keywords
cancer
compound
subject
carcinoma
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540921A5 (https=
Inventor
ダニエル ヘラー
クリストファー ホロスコ
Original Assignee
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2022540921A publication Critical patent/JP2022540921A/ja
Publication of JP2022540921A5 publication Critical patent/JP2022540921A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022502559A 2019-07-15 2020-07-15 Ｋｒａｓまたはｈｒａｓ変異若しくは増幅を有するがんを処置する際に有用な方法 Pending JP2022540921A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874474P 2019-07-15 2019-07-15
US62/874,474 2019-07-15
PCT/US2020/042162 WO2021011674A1 (en) 2019-07-15 2020-07-15 Methods useful in treating cancers harboring a kras or hras mutation or amplification

Publications (2)

Publication Number Publication Date
JP2022540921A true JP2022540921A (ja) 2022-09-20
JP2022540921A5 JP2022540921A5 (https=) 2023-07-26

Family

ID=74211326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502559A Pending JP2022540921A (ja) 2019-07-15 2020-07-15 Ｋｒａｓまたはｈｒａｓ変異若しくは増幅を有するがんを処置する際に有用な方法

Country Status (7)

Country Link
US (1) US20220257599A1 (https=)
EP (1) EP3999049A4 (https=)
JP (1) JP2022540921A (https=)
CN (1) CN114364377A (https=)
AU (1) AU2020315388A1 (https=)
CA (1) CA3147588A1 (https=)
WO (1) WO2021011674A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102679204B1 (ko) * 2021-02-10 2024-06-27 한국생명공학연구원 GPX4 저해제 및 Lp-PLA2 저해제를 포함하는 암 예방 또는 치료용 조성물
WO2024077085A1 (en) * 2022-10-07 2024-04-11 Memorial Sloan-Kettering Cancer Center Targeting phospholipase a2 (pla2) in cancer
US12314787B2 (en) 2023-04-27 2025-05-27 Hewlett Packard Enterprise Development Lp Serving application programming interface calls directed to hierarchical data format files stored in fabric-attached memories

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012138877A1 (en) * 2011-04-06 2012-10-11 The Scripps Research Institute N1- and n2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods
US20150017671A1 (en) * 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102166364A (zh) * 2011-04-14 2011-08-31 江南大学 用于治疗卵巢癌的钙离子非依赖性磷脂酶a2的抑制剂
KR20160117596A (ko) * 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
AU2017329090B9 (en) * 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017671A1 (en) * 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
WO2012138877A1 (en) * 2011-04-06 2012-10-11 The Scripps Research Institute N1- and n2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAGANO JMG ET AL.: "Optimization and characterization of a carbamate inhibitor for plasma platelet-activating factor ace", PROBE REPORTS FROM THE NIH MOLECULAR LIBRARIES PROGRAM, JPN6024023444, 2014, pages 1 - 45, ISSN: 0005504892 *

Also Published As

Publication number Publication date
WO2021011674A1 (en) 2021-01-21
EP3999049A1 (en) 2022-05-25
AU2020315388A1 (en) 2022-02-17
CN114364377A (zh) 2022-04-15
EP3999049A4 (en) 2023-07-26
CA3147588A1 (en) 2021-01-21
US20220257599A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
Pathak et al. Dichotomous role of the human mitochondrial Na+/Ca2+/Li+ exchanger NCLX in colorectal cancer growth and metastasis
Singh et al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway
Zhang et al. Adipocyte-derived lipids mediate melanoma progression via FATP proteins
Rysman et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation
McHugh et al. COPI vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cells
Kim et al. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α
JP2021185210A (ja) 抗癌療法としての正常細胞および腫瘍細胞の小分子ｔｒａｉｌ遺伝子誘導
Fridlich et al. BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication
JP2022540921A (ja) Ｋｒａｓまたはｈｒａｓ変異若しくは増幅を有するがんを処置する際に有用な方法
Francis et al. H3 histamine receptor–mediated activation of protein kinase Cα Inhibits the growth of cholangiocarcinoma in vitro and in vivo
US20140294994A1 (en) Pharmaceutical composition for elimination of cancer stem cells
US10898473B2 (en) Combinations to treat cancer
Zhao et al. Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway
Qin et al. CCT251545 enhances drug delivery and potentiates chemotherapy in multidrug-resistant cancers by Rac1-mediated macropinocytosis
Zhu et al. Methylglyoxal deteriorates macrophage efferocytosis in diabetic wounds through ROS-induced ubiquitination degradation of KLF4
Saxena et al. Preclinical development of a nontoxic oral formulation of monoethanolamine, a lipid precursor, for prostate cancer treatment
Kang et al. Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modulation of β-catenin signaling axis in gastric cancer-initiating cells
US20190201416A1 (en) Pharmaceutical composition for treatment of lung cancer comprising glucocorticoid-based compound
Gomaa et al. SOX9 is regulated by AURKA in response to Helicobacter pylori infection via EIF4E-mediated cap-dependent translation
JP7656922B2 (ja) Ｒａｄ５１阻害薬としての求電子剤および求電子剤プロドラッグ
WO2016076359A1 (ja) イベルメクチン又はミルベマイシンｄを有効成分として含む抗癌剤
Wang et al. Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer
US20220288130A1 (en) Compositions and methods for diagnosis and treatment of metabolic diseases and disorders
US20150352076A1 (en) Molecularly targeted combination drug for tumor treatment and prevention
TW201628624A (zh) 使用啡噻嗪用於治療癌症的醫藥組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230718

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250116